NCT05262959View on ClinicalTrials.gov

A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

May 30, 2024

Conditions
Donafenib
Interventions
DRUG

Donafenib, PD-1

Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.

PROCEDURE

TACE

TACE will be performed by the investigator based on the patient's tumor status.

Trial Locations (1)

200032

Zhongshan Hospital, Fudan University,, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT05262959 - A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC | Biotech Hunter | Biotech Hunter